| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-191 | |
| Phytochemical name or plant extracts | LXY6090 - a novel manassantin A derivative | |
| PMID | 27445487 | |
| Literature evidence | In conclusion, our data provide a basis for the future development of the novel compound LXY6090 as a potential therapeutic agent for breast cancer. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Lignan | |
| Source of phytochemicals or plant Extracts | Saururus cernuus | |
| Geographical availability | Alabama, Arkansas, Delaware, District of Columbia, Florida, Georgia, Illinois, Indiana, Kansas, Kentucky, Louisiana, Maine, Maryland, Mexico Northeast, Mexico Southwest, Michigan, Mississippi, Missouri, New Jersey, New York, North Carolina, Ohio, Oklahoma, Ontario, Pennsylvania, Québec, Rhode I., South Carolina, Tennessee, Texas, Virginia, West Virginia, Wisconsin | |
| Plant parts | NA | |
| Other cancers | Breast cancer | |
| Target gene or protein | HIF-1, VEGF, IGF-2 | |
| Gene or Protein evidence | The related biological evaluation showed that the activity of HIF-1 target genes, VEGF and IGF-2, was decreased by LXY6090 in breast cancer cell lines. | |
| Target pathways | NA | |
| IC50 | 245.7±15.2 nmol/L against T47D 352.7±14.2 nmol/L against MCF-7 | |
| Potency | Furthermore, LXY6090 inhibited HIF-1 activity with an IC50 value of 4.11±0.4 nM, which is much lower than that of MA (35.2±4.7 nM) | |
| Cell line/ mice model | T47D, MCF-7 | |
| Additional information | Furthermore, LXY6090 showed in vivo anticancer efficacy by decreasing the HIF-1α expression in nude mice bearing MX-1 tumor xenografts. In conclusion, our data provide a basis for the future development of the novel compound LXY6090 as a potential therapeutic agent for breast cancer. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:284624-2 | |
| Safety | NA |